Apricoxib
![]() | |
Identifiers | |
---|---|
| |
CAS Number | 162011-90-7 |
PubChem (CID) | 9820073 |
ChemSpider | 7995822 |
Chemical and physical data | |
Formula | C19H20N2O3S |
Molar mass | 356.4387 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Apricoxib is an experimental anticancer drug in Phase II clinical trials. It is a COX-2 inhibitor which improves standard therapy response in molecularly defined models of pancreatic cancer.[1]
See also
References
- ↑ Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453.
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.